Loading...
•
Mar 31, 2023
Iovance Q1 2023 Earnings Report
Iovance reported first quarter 2023 financial results and corporate updates.
Key Takeaways
Iovance Biotherapeutics reported a net loss of $107.4 million, or $0.50 per share, for the first quarter ended March 31, 2023. The company's cash, cash equivalents, investments and restricted cash totaled $632.7 million at March 31, 2023. They expect the cash position is sufficient to fund operations into the second half of 2024.
Completed the first Biologics License Application (BLA) submission in March 2023.
Commercial readiness activities are on track to support the potential commercial launch of Lifileucel in 2023.
Net loss for the first quarter ended March 31, 2023, was $107.4 million, or $0.50 per share.
Cash, cash equivalents, investments and restricted cash totaled $632.7 million at March 31, 2023.
Forward Guidance
Iovance expects that its current cash position is sufficient to fund its operating plan into the second half of 2024, including the Proleukin® acquisition, commercial launch preparations, internal manufacturing and clinical pipeline expansion.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...